Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349816 · ClinicalTrials.gov registry record · Phase 2
PT003 MDI Dose Confirmation Study
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT01349816 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 185 participants.
The verdict
NCT01349816, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG PT003
- DRUG PT001
- DRUG PT005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349816
The ClinicalTrials.gov registry entry for NCT01349816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PT003 is the first listed.
NCT01349816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349816 about?
NCT01349816 is a clinical study titled "PT003 MDI Dose Confirmation Study". The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT01349816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2011-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01349816?
The interventions under investigation include: PT003 (DRUG), PT001 (DRUG), PT005 (DRUG).
Who is sponsoring clinical trial NCT01349816?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.